Percutaneous coronary intervention (PCI) with a drug-eluting stent (DES) is routine treatment for patients with acute coronary syndromes (ACS). However, permanent metallic caging of the vessel has several shortcomings, such as side branch jailing and impossibility of late lumen enlargement. Moreover, DES PCI is affected by vasomotion impairment. In ACS a high thrombus burden and vasospasm lead to a higher risk of acute and late acquired stent malapposition than in stable patients. This increases the risk of acute, late and very late stent thrombosis. In this challenging clinical setting, the implantation of bioresorbable vascular scaffolds (BVS) could represent an appealing therapeutic option. Temporary vessel scaffolding has proved to have several advantages over metallic stent delivery, such as framework reabsorption, late lumen enlargement, side branch patency, and recovery of physiological reactivity to vasoactive stimuli. In the thrombotic environment of ACS, BVS implantation has the benefit of capping the thrombus and the vulnerable plaque. Bioresorbable vascular scaffolds also seems to reduce the incidence of angina during follow-up. Acute coronary syndromes patients may therefore benefit more from temporary polymeric caging than from permanent stent platform implantation. The aim of this review is to update the available knowledge concerning the use of BVS in ACS patients, by analyzing the potential pitfalls in this challenging clinical setting and presenting tricks to overcome these limitations.
Introduction
Percutaneous coronary intervention (PCI) with a metallic stent and in particular with a second generation drug-eluting stent (DES) may be considered as the gold standard treatment for patients presenting with acute coronary syndrome (ACS) [1] . However, permanent delivery of a metallic platform is affected by several drawbacks, such as caging of the vessel, side branches jailing, impairment of vasomotion and impossibility of lumen enlargement [2] . Furthermore, PCI in the context of ACS portends a higher risk of acute and late acquired stent malapposition than in stable patients, due to stent undersizing for vasospasm and thrombus sequestration behind the struts [3, 4] . Bioresorbable vascular scaffolds (BVS) could represent a good therapeutic option to overcome these drawbacks of metallic stents.
The aim of this review is to update the available data concerning the use of BVS in ACS patients, to analyze potential pitfalls in this thrombotic environment, and to provide tips to overcome these limitations.
Bioresorbable vascular scaffolds: a new therapeutic tool for acute coronary syndrome patients
Patients suffering from ACS are often young and therefore have long life expectancy. Ruptured plaques are usually soft with a relatively small plaque burden. Most of the current evidence concerning the use of BVS resides in the experience of the Absorb bioresorbable scaffold (Abbott Vascular, Santa Clara, CA, USA).
The polymeric structure of Absorb consists of a backbone of poly-L-lactide (PLLA) coated with poly-D,L-lactide (PDLLA), which contains and controls the release of the drug everolimus. Chains of PLLA and PDLLA are progressively shortened as ester bonds between lactide units are hydrolyzed. Poly-L-lactide and PDLLA fully degrade to lactic acid that is metabolized via the Krebs cycle to H 2 O and CO 2 . Small particles are phagocytosed by macrophages [5] .
This polymeric structure of the Absorb seems to favor the formation of a thin layer of neointimal tissue over a hypothetical thin-cap fibroatheroma responsible for the ACS [6, 7] . Moreover, at long-term follow-up the implantation of an Absorb BVS is associated with lumen enlargement, side branch patency, strut reabsorption and recovery of physiological reactivity to vasoactive stimuli [8, 9] . Finally, the complete bioresorption of polymeric struts may also be associated with a reduction in incidence of angina during follow-up [10] . Acute coronary syndrome patients may therefore benefit more from temporary polymeric caging than from permanent stent implantation [11] .
Bioresorbable vascular scaffolds in acute coronary syndrome: data from registries and clinical trials
Currently available data are mostly limited to observational registries and a few randomized trials (Table I) [26] . Overall, a total of 240 patients were randomly assigned 1 : 1 : 1 to the BVS, EES (Promus Element; Boston Scientific, Marlborough, Massachusetts) or Biolimus-eluting stent (Biomatrix Flex, Biosensors Europe SA, Morges, Switzerland) group. Nine-month late lumen loss as the primary endpoint did not differ between groups. There were no differences in patientand device-oriented endpoints. No stent thrombosis was reported in the DES group, whereas one possible late scaffold thrombosis was reported in the BVS arm. Based on these data, BVS implantation in ACS seems to be feasible. No definite conclusions may be drawn about scaffold thrombosis, due to discordance between the various studies, which are not powered for this endpoint. The data from ongoing registries and randomized trials will help to completely assess BVS safety and efficacy in ACS (Table II) . Among the ongoing randomized trials, the ISAR-ABSORB-MI trial (NCT01942070) with an angiographic outcome at 9 months and the TROFI-II study (NCT01986803) with an optical coherence tomography derived endpoint at 6 months will shed light on the safety and midterm efficacy of these devices as compared to second generation DES.
Procedural aspects: bioresorbable vascular scaffolds limitations and technical tricks
Although preliminary clinical experience with BVS in ACS is promising, some technical limitations should be considered [27] . 
ACS -Acute coronary syndrome, BVS -bioresorbable vascular scaffold, CABG -coronary artery bypass graft, MACE -major adverse cardiovascular event, MI -myocardial infarction, MLA -minimal lumen area, OCT -optical coherence tomography, RVD -reference vessel diameter, STEMI -ST-elevation myocardial infarction, TIMI -thrombolysis in myocardial infarction, TLR -target lesion revascularization, TVF -target vessel failure, TV-MI -target vessel myocardial infarction, TVR -target vessel revascularization.
Due to low polymer radial strength, optimal lesion preparation is mandatory; when inflated balloons are not well expanded, lesion preparation should be improved with short high-pressure balloons [27, 28] . However, pre-dilation prolongs the procedural time and fluoroscopy time and increases the volume of contrast administered. This is an important issue especially in hemodynamically unstable patients (for example "last remaining vessel patients"), in whom the need for pre-, post-dilatation and prolonged scaffold inflation can be an important limitation. In any case, direct scaffolding is feasible (32.7% in the BVS STEMI first study), but there are no data on outcome [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] .
Post-dilatation is also an important step, and it has to be performed with a non-compliant balloon in a balloon-artery ratio of 1 : 1, the size of the implanted BVS not exceeding 0.5 mm [29] .
Scaffold thrombosis appeared to be the most important limitation of polymeric scaffolds in the early phase after implantation [20, 25, 30] (Figure 1 ). It can be linked to several factors. First, current generation BVS present a rather bulky structure (strut thickness ≈ 150 µm) [31] . Acute and chronic inflammatory reaction following BVS implantation could also play a role [32] . The presence of a high thrombus burden in the context of STEMI and post-procedure enhanced platelet reactivity could facilitate the thrombosis [33] . Some procedure-related factors, such as acute incomplete apposition or inappropriate vessel sizing, could also be taken into account [33, 34] (Figure 2) . Vasoconstriction of coronary arteries and the presence of thrombus are common features in the context of ACS. These features should be taken into consideration to correctly select the scaffold size [27] . In this scenario, several thrombectomy crossings and the use of intracoronary nitrates may be helpful. Although routine use of thrombectomy did not demonstrate any clinical benefit [1, 35] , when BVS implantation in ACS is planned, the use of a manual aspiration catheter may provide an additional value beyond thrombus removal and BVS sizing, for example in prediction of lesion crossability by BVS [27] .
The use of intracoronary imaging is encouraged especially during the initial implants. Intravascular ultrasound imaging may facilitate correct balloon and scaffold sizing as well as evaluation of BVS expansion. Optical coherence tomography may obtain more accurate images of BVS integrity, apposition and presence of residual thrombus or edge dissections [27] .
The antiplatelet regimen is another critical issue of BVS in ACS. Although no specific recommendations are given in the guidelines [1] , it is advisable to optimize the antithrombotic regimen in the acute phase (i.e. use of IIb/IIIa inhibitors) and to use the most potent oral agents available (prasugrel or ticagrelor). Regarding the duration of double antiplatelet therapy (DAPT) the evidence is still lacking, as the latest trials testing shortening of DAPT do not apply to BVS [36, 37] . Twelve months is recommended for ACS patients, according to current guidelines [1] . However, in the case of complex procedures, with multiple overlapping scaffolds, for example, it may be recommended to prolong DAPT [38] .
Future bioresorbable vascular scaffolds developments in acute coronary syndrome
Current CE-approved BVS are the Absorb (Abbott Vascular, Santa Clara, CA, USA) and the DESolve (Elixir Medical Corporation, Sunnyvale, CA, USA) [39] . Both are made of poly-lactic acid and have strut thickness of 150 µm.
The DESolve [40, 41] has a larger range of expansion than the BVS, with the peculiarity of "self-correction" acute recoil. In the first-in-man study it showed good efficacy and safety in 16 enrolled subjects (stable angina Figure 2 . Algorithm for treatment of early scaffold thrombosis. Early scaffold thrombosis can be treated with stent implantation or not. A stent should be implanted in case of scaffold fracture or when the final desired diameter is beyond the BVS scale. Conversely, scaffold post-dilatation can be a good option when the final desired diameter is within the BVS range, when the BVS in under-expanded, or when no mechanical issue can be detected (adapted from reference [27] [42] is recruiting patients with acute myocardial infarction. This is a prospective, single-arm, multi-center, observational registry, aiming to assess clinical outcome with Elixir BVS in the "real world". The primary outcome is the MACE (cardiac death, target vessel myocardial infarction and target lesion revascularization) rate at 1-year clinical follow-up. Scaffold thrombosis is also assessed. New BVS platforms are currently under development, aiming to reduce strut thickness and improve scaffold distensibility (Table III) . Drug kinetics, materials and bioresorption rate will also differ. Therefore, accurate knowledge of the new devices and future trials to test the safety and efficacy of second generation BVS are warranted.
Conclusions
Clinical experience of BVS implantation in ACS is currently limited. Available data suggest good acute and midterm performance. Lesion preparation, adequate vessel sizing (including with the use of intravascular imaging techniques), attention to BVS expansion limits, post-dilatation and importance of optimized DAPT are mainstays of BVS PCI [27, 43] .
The early scaffold thrombosis rate appears to be higher than expected in a few registries. In this regard, largescale randomized trials with long-term follow-up will determine the potential and limitations of the current generation BVS in this context. Finally, the new generation BVS may overcome most of the current technical pitfalls and may therefore improve clinical outcomes. 
